APA (7th ed.) Citation

Wolters, E. E., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Hansson, O., . . . Ossenkoppele, R. (2021). Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. European Journal of Nuclear Medicine & Molecular Imaging, 48(7), 2097. https://doi.org/10.1007/s00259-020-05118-w

Chicago Style (17th ed.) Citation

Wolters, E. E., et al. "Clinical Validity of Increased Cortical Uptake of [18F]flortaucipir on PET as a Biomarker for Alzheimer's Disease in the Context of a Structured 5-phase Biomarker Development Framework." European Journal of Nuclear Medicine & Molecular Imaging 48, no. 7 (2021): 2097. https://doi.org/10.1007/s00259-020-05118-w.

MLA (9th ed.) Citation

Wolters, E. E., et al. "Clinical Validity of Increased Cortical Uptake of [18F]flortaucipir on PET as a Biomarker for Alzheimer's Disease in the Context of a Structured 5-phase Biomarker Development Framework." European Journal of Nuclear Medicine & Molecular Imaging, vol. 48, no. 7, 2021, p. 2097, https://doi.org/10.1007/s00259-020-05118-w.